Press Releases

DAY HI:
DAY LOW:
VOLUME:

Copyright West LLC. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Aug 14, 2017
Qapzola is a novel drug activated by DT-diaphorase, an enzyme over-expressed in bladder cancer cells, to generate cytotoxic species leading to cell death. NMIBC is the fifth most common cancer in the U.S. with the highest lifetime cost per patient. It is an unmet medical need due to high recurrence
Aug 03, 2017
ROLONTIS™ (eflapegrastim): BLA filing expected next year. Enrollment completed in registrational ADVANCE Study under a Special Protocol Assessment (SPA) with the FDA . Topline results expected in Q1 2018. A second smaller study RECOVER is enrolling patients in EU and U.S.
Aug 01, 2017
Enrollment completed ahead of schedule. The Company plans to announce topline data in Q1 2018 and file a Biologics License Application (BLA) next year. To strengthen the regulatory package for U.S. and EU, the Company is enrolling patients in an additional international Phase 3 study (RECOVER),
Jul 27, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to
Jun 19, 2017
The FOLOTYN (antifolate) and an HDAC inhibitor (romidepsin) combination was shown to achieve a 71% overall response rate (ORR) among PTCL patients. HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug
Jun 02, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced presentations of clinical data for FOLOTYN ® (pralatrexate
May 30, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
May 16, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
May 02, 2017
ROLONTIS™ (eflapegrastim): Phase 3 ADVANCE Pivotal study: Number of evaluable patients reduced to 400 from 580, per an amended Special Protocol Assessment (SPA) received from the FDA . ADVANCE study is 75% enrolled and the Company expects to complete enrollment in the second half of this year.
Apr 27, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
Apr 25, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to
Apr 04, 2017
ROLONTIS is currently in a pivotal clinical development program and is on track for Spectrum to file BLA next year. Eflapegrastim was more potent than pegfilgrastim at G-CSF equivalent doses in this neutropenic rat model. HENDERSON, Nev --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI),
Mar 31, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its
Mar 30, 2017
Encouraging results observed in patient with exon 20 insertion mutation treated with poziotinib on a compassionate basis. Phase 2 trial will evaluate Objective Response Rate (ORR) as the primary endpoint. Top-line results are expected before year-end.
Mar 08, 2017
ROLONTIS™ (eflapegrastim) pivotal program is on track for Spectrum to file BLA next year. Poziotinib study in non-small cell lung cancer patients with EGFR Exon 20 insertion mutations, being run in partnership with The University of Texas MD Anderson Cancer Center , is expected to yield results
Mar 01, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to
Feb 16, 2017
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI) , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and
Dec 08, 2016
Pre-clinical results show poziotinib could potentially be effective in patients with non-small cell lung cancer with EGFR exon 20 mutations. Computational modeling suggests that due to its small size, poziotinib may overcome the steric hindrance of the drug binding pocket.
Dec 06, 2016
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology announced the presentation of data from a case match control analysis of the PROPEL
Dec 05, 2016
HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of clinical and scientific data related to its
Displaying 81 - 100 of 791